Safety Study of TAK-700 in Subjects With Prostate Cancer.

NCT ID: NCT00569153

Last Updated: 2016-04-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 123 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30
• Study Completion Date: 2013-02-28

Brief Summary

The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.

Conditions

Prostatic Neoplasms

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1 (TAK-700)

Group Type: EXPERIMENTAL

TAK-700

Intervention Type: DRUG

Phase 1 portion of study:

TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.

Phase 2 portion of study:

Patients will receive one of 4 treatments:

• TAK-700 at 300 mg twice/day
• TAK-700 at 400 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg once/day in the morning

Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)

Group Type: EXPERIMENTAL

TAK-700

Intervention Type: DRUG

Phase 1 portion of study:

TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.

Phase 2 portion of study:

Patients will receive one of 4 treatments:

• TAK-700 at 300 mg twice/day
• TAK-700 at 400 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg once/day in the morning

Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)

Group Type: EXPERIMENTAL

TAK-700

Intervention Type: DRUG

Phase 1 portion of study:

TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.

Phase 2 portion of study:

Patients will receive one of 4 treatments:

• TAK-700 at 300 mg twice/day
• TAK-700 at 400 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg once/day in the morning

Arm 4 (TAK-700 at 600 mg)

Group Type: EXPERIMENTAL

TAK-700

Intervention Type: DRUG

Phase 1 portion of study:

TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.

Phase 2 portion of study:

Patients will receive one of 4 treatments:

• TAK-700 at 300 mg twice/day
• TAK-700 at 400 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg once/day in the morning

Interventions

TAK-700

Phase 1 portion of study:

TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.

Phase 2 portion of study:

Patients will receive one of 4 treatments:

• TAK-700 at 300 mg twice/day
• TAK-700 at 400 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg and 5 mg prednisone twice/day
• TAK-700 at 600 mg once/day in the morning

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject is male and at least 18 years of age.
• Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with metastatic, progressive disease while on androgen deprivation therapy.
• Subject has radiograph-documented (computed tomography, magnetic resonance imaging or x-ray) metastatic disease.
• Subject has undergone orchiectomy or is expected to continue receiving luteinizing hormone-releasing hormone analogue therapy, and has a testosterone level of <50 ng/dL at screening.
• Subject has discontinued all antiandrogen therapy (within 30 days for flutamide and within 6 weeks for all others) prior to their first dose of study drug.
• Subject has a prostate-specific antigen level ≥5 ng/mL.
• Subject meets all screening laboratory values as specified in the protocol.
• Subject has a screening ejection fraction that is above the lower limit of the institutional normal range.
• Subject has ECOG performance status of 0 to 2.
• Subject has normal or, in the opinion of the investigator, clinically insignificant, physical examination findings, ECG and chest x-ray results.
• Subjects, even if surgically sterilized (ie, status postvasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.

Exclusion Criteria

• Subject has known hypersensitivity to TAK-700 or related compounds.
• Subject has received prior therapy with aminoglutethimide or ketoconazole within 30 days prior to the first dose of study drug.
• Subject has received prior chemotherapy for prostate cancer.
• Subject has received any investigational compound within 30 days prior to first dose of study drug.
• Subject has received prior herbal product known to decrease prostate-specific antigen levels (eg, Saw Palmetto, PC-SPES) within 30 days prior to the first dose of study drug.
• Subject has received radiation therapy for prostate cancer within 30 days prior to first dose of study drug.
• Chronic therapy with oral or other systemically administered corticosteroids, such as prednisone, within 30 days prior to Screening. Chronic therapy is defined as the use of corticosteroids for more than 7 days within a 30-day period.
• Subject has current spinal cord compression, current bilateral hydronephrosis, or current bladder neck outlet obstruction.
• Subject has a history of adrenal insufficiency.
• Subject has a history of myocardial infarction, ischaemic symptomatic heart disease, cardiac arrhythmias or thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 12 months prior to first dose of study drug.
• Subject has any symptoms which the investigator deems related to prostate cancer, i.e., bone pain, pelvic pain.
• Subject has a history of congestive heart failure (New York Heart Association Class II or greater.
• Subject has history of another malignancy other than basal cell carcinoma or state 1 squamous cell carcinoma of the skin, within the last 5 years.
• Subject has uncontrolled hypertension.
• Subject is known to have HIV infection, chronic Hepatitis B or C or any other serious medical condition or psychiatric illness that might affect life expectancy or make it difficult to successfully manage and follow the subject according to protocol.
• Subject is unable to understand verbal or written English or any other language for which a certified translation of the institutional review board (IRB)-approved informed consent has been provided.
• Subject is unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Millennium Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Millennium Pharmaceuticals, Inc.

Locations

USC Westside Prostate Cancer Center

Beverly Hills, California, United States

University of Southern California

Los Angeles, California, United States

The Angeles Clinic and Research Institute

Los Angeles, California, United States

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

South Florida Medical Research

Aventura, Florida, United States

Florida Cancer Specialists

Fort Myers, Florida, United States

Northwestern University Medical Center

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States

University of Chicago Pharmacy

Chicago, Illinois, United States

Evanston Hospital

Evanston, Illinois, United States

Kellogg Pharmacy - Evanston Hospital

Evanston, Illinois, United States

NorthShore University HealthSystem

Evanston, Illinois, United States

Kellogg Cancer Care Center

Glenview, Illinois, United States

Hematology/Oncology Associates of Central New York

East Syracuse, New York, United States

Gabrail Cancer Center

Canton, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Taussig Cancer Institute

Cleveland, Ohio, United States

Tennessee Oncology

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

TAK-700-201

Identifier Type: -

Identifier Source: secondary_id

TAK-700_201

Identifier Type: -

Identifier Source: org_study_id